Genemed: An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials

Yingdong Zhao, Eric Polley, Ming Chung Li, Chih Jian Lih, Alida Palmisano, David J. Sims, Lawrence V. Rubinstein, Barbara A. Conley, Alice P. Chen, P. Mickey Williams, Shivaani Kummar, James H. Doroshow, Richard M. Simon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We have developed an informatics system, GeneMed, for the National Cancer Institute (NCI) molecular profiling-based assignment of cancer therapy (MPACT) clinical trial (NCT01827384) being conducted in the National Institutes of Health (NIH) Clinical Center. This trial is one of the first to use a randomized design to examine whether assigning treatment based on genomic tumor screening can improve the rate and duration of response in patients with advanced solid tumors. An analytically validated next-generation sequencing (NGS) assay is applied to DNA from patients’ tumors to identify mutations in a panel of genes that are thought likely to affect the utility of targeted therapies available for use in the clinical trial. The patients are randomized to a treatment selected to target a somatic mutation in the tumor or with a control treatment. The GeneMed system streamlines the workflow of the clinical trial and serves as a communications hub among the sequencing lab, the treatment selection team, and clinical personnel. It automates the annotation of the genomic variants identified by sequencing, predicts the functional impact of mutations, identifies the actionable mutations, and facilitates quality control by the molecular characterization lab in the review of variants. The GeneMed system collects baseline information about the patients from the clinic team to determine eligibility for the panel of drugs available. The system performs randomized treatment assignments under the oversight of a supervising treatment selection team and generates a patient report containing detected genomic alterations. NCI is planning to expand the MPACT trial to multiple cancer centers soon. In summary, the GeneMed system has been proven to be an efficient and successful informatics hub for coordinating the reliable application of NGS to precision medicine studies.

Original languageEnglish (US)
Pages (from-to)45-55
Number of pages11
JournalCancer Informatics
Volume14
DOIs
StatePublished - Mar 19 2015
Externally publishedYes

Fingerprint

Informatics
Clinical Trials
Neoplasms
Mutation
Therapeutics
National Cancer Institute (U.S.)
Precision Medicine
Workflow
National Institutes of Health (U.S.)
Quality Control
Communication
DNA

Keywords

  • Clinical trial
  • GeneMed
  • Informatics system
  • MPACT
  • Next-generation sequencing
  • Precision medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genemed : An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials. / Zhao, Yingdong; Polley, Eric; Li, Ming Chung; Lih, Chih Jian; Palmisano, Alida; Sims, David J.; Rubinstein, Lawrence V.; Conley, Barbara A.; Chen, Alice P.; Williams, P. Mickey; Kummar, Shivaani; Doroshow, James H.; Simon, Richard M.

In: Cancer Informatics, Vol. 14, 19.03.2015, p. 45-55.

Research output: Contribution to journalArticle

Zhao, Y, Polley, E, Li, MC, Lih, CJ, Palmisano, A, Sims, DJ, Rubinstein, LV, Conley, BA, Chen, AP, Williams, PM, Kummar, S, Doroshow, JH & Simon, RM 2015, 'Genemed: An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials', Cancer Informatics, vol. 14, pp. 45-55. https://doi.org/10.4137/CIN.S17282
Zhao, Yingdong ; Polley, Eric ; Li, Ming Chung ; Lih, Chih Jian ; Palmisano, Alida ; Sims, David J. ; Rubinstein, Lawrence V. ; Conley, Barbara A. ; Chen, Alice P. ; Williams, P. Mickey ; Kummar, Shivaani ; Doroshow, James H. ; Simon, Richard M. / Genemed : An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials. In: Cancer Informatics. 2015 ; Vol. 14. pp. 45-55.
@article{d4b872262c364522b1c4cccaac3b0adc,
title = "Genemed: An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials",
abstract = "We have developed an informatics system, GeneMed, for the National Cancer Institute (NCI) molecular profiling-based assignment of cancer therapy (MPACT) clinical trial (NCT01827384) being conducted in the National Institutes of Health (NIH) Clinical Center. This trial is one of the first to use a randomized design to examine whether assigning treatment based on genomic tumor screening can improve the rate and duration of response in patients with advanced solid tumors. An analytically validated next-generation sequencing (NGS) assay is applied to DNA from patients’ tumors to identify mutations in a panel of genes that are thought likely to affect the utility of targeted therapies available for use in the clinical trial. The patients are randomized to a treatment selected to target a somatic mutation in the tumor or with a control treatment. The GeneMed system streamlines the workflow of the clinical trial and serves as a communications hub among the sequencing lab, the treatment selection team, and clinical personnel. It automates the annotation of the genomic variants identified by sequencing, predicts the functional impact of mutations, identifies the actionable mutations, and facilitates quality control by the molecular characterization lab in the review of variants. The GeneMed system collects baseline information about the patients from the clinic team to determine eligibility for the panel of drugs available. The system performs randomized treatment assignments under the oversight of a supervising treatment selection team and generates a patient report containing detected genomic alterations. NCI is planning to expand the MPACT trial to multiple cancer centers soon. In summary, the GeneMed system has been proven to be an efficient and successful informatics hub for coordinating the reliable application of NGS to precision medicine studies.",
keywords = "Clinical trial, GeneMed, Informatics system, MPACT, Next-generation sequencing, Precision medicine",
author = "Yingdong Zhao and Eric Polley and Li, {Ming Chung} and Lih, {Chih Jian} and Alida Palmisano and Sims, {David J.} and Rubinstein, {Lawrence V.} and Conley, {Barbara A.} and Chen, {Alice P.} and Williams, {P. Mickey} and Shivaani Kummar and Doroshow, {James H.} and Simon, {Richard M.}",
year = "2015",
month = "3",
day = "19",
doi = "10.4137/CIN.S17282",
language = "English (US)",
volume = "14",
pages = "45--55",
journal = "Cancer Informatics",
issn = "1176-9351",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Genemed

T2 - An informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials

AU - Zhao, Yingdong

AU - Polley, Eric

AU - Li, Ming Chung

AU - Lih, Chih Jian

AU - Palmisano, Alida

AU - Sims, David J.

AU - Rubinstein, Lawrence V.

AU - Conley, Barbara A.

AU - Chen, Alice P.

AU - Williams, P. Mickey

AU - Kummar, Shivaani

AU - Doroshow, James H.

AU - Simon, Richard M.

PY - 2015/3/19

Y1 - 2015/3/19

N2 - We have developed an informatics system, GeneMed, for the National Cancer Institute (NCI) molecular profiling-based assignment of cancer therapy (MPACT) clinical trial (NCT01827384) being conducted in the National Institutes of Health (NIH) Clinical Center. This trial is one of the first to use a randomized design to examine whether assigning treatment based on genomic tumor screening can improve the rate and duration of response in patients with advanced solid tumors. An analytically validated next-generation sequencing (NGS) assay is applied to DNA from patients’ tumors to identify mutations in a panel of genes that are thought likely to affect the utility of targeted therapies available for use in the clinical trial. The patients are randomized to a treatment selected to target a somatic mutation in the tumor or with a control treatment. The GeneMed system streamlines the workflow of the clinical trial and serves as a communications hub among the sequencing lab, the treatment selection team, and clinical personnel. It automates the annotation of the genomic variants identified by sequencing, predicts the functional impact of mutations, identifies the actionable mutations, and facilitates quality control by the molecular characterization lab in the review of variants. The GeneMed system collects baseline information about the patients from the clinic team to determine eligibility for the panel of drugs available. The system performs randomized treatment assignments under the oversight of a supervising treatment selection team and generates a patient report containing detected genomic alterations. NCI is planning to expand the MPACT trial to multiple cancer centers soon. In summary, the GeneMed system has been proven to be an efficient and successful informatics hub for coordinating the reliable application of NGS to precision medicine studies.

AB - We have developed an informatics system, GeneMed, for the National Cancer Institute (NCI) molecular profiling-based assignment of cancer therapy (MPACT) clinical trial (NCT01827384) being conducted in the National Institutes of Health (NIH) Clinical Center. This trial is one of the first to use a randomized design to examine whether assigning treatment based on genomic tumor screening can improve the rate and duration of response in patients with advanced solid tumors. An analytically validated next-generation sequencing (NGS) assay is applied to DNA from patients’ tumors to identify mutations in a panel of genes that are thought likely to affect the utility of targeted therapies available for use in the clinical trial. The patients are randomized to a treatment selected to target a somatic mutation in the tumor or with a control treatment. The GeneMed system streamlines the workflow of the clinical trial and serves as a communications hub among the sequencing lab, the treatment selection team, and clinical personnel. It automates the annotation of the genomic variants identified by sequencing, predicts the functional impact of mutations, identifies the actionable mutations, and facilitates quality control by the molecular characterization lab in the review of variants. The GeneMed system collects baseline information about the patients from the clinic team to determine eligibility for the panel of drugs available. The system performs randomized treatment assignments under the oversight of a supervising treatment selection team and generates a patient report containing detected genomic alterations. NCI is planning to expand the MPACT trial to multiple cancer centers soon. In summary, the GeneMed system has been proven to be an efficient and successful informatics hub for coordinating the reliable application of NGS to precision medicine studies.

KW - Clinical trial

KW - GeneMed

KW - Informatics system

KW - MPACT

KW - Next-generation sequencing

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=84925357033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925357033&partnerID=8YFLogxK

U2 - 10.4137/CIN.S17282

DO - 10.4137/CIN.S17282

M3 - Article

AN - SCOPUS:84925357033

VL - 14

SP - 45

EP - 55

JO - Cancer Informatics

JF - Cancer Informatics

SN - 1176-9351

ER -